Eone Diagnomics Genome Center Co Ltd
KOSDAQ:245620
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Eone Diagnomics Genome Center Co Ltd
Research & Development
Eone Diagnomics Genome Center Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Eone Diagnomics Genome Center Co Ltd
KOSDAQ:245620
|
Research & Development
-₩1.5B
|
CAGR 3-Years
34%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Research & Development
-₩37.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
A
|
ADM Korea Inc
KOSDAQ:187660
|
Research & Development
-₩2.1B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Research & Development
-₩15.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-23%
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Research & Development
-₩20.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Research & Development
-₩171.1B
|
CAGR 3-Years
-72%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-36%
|
|
Eone Diagnomics Genome Center Co Ltd
Glance View
EONE DIAGNOMICS GENOME CENTER Co., Ltd. engages in the operation as a genomics company providing a range of clinical and consumer genetic services. The company is headquartered in Incheon, Incheon. The company went IPO on 2018-06-26. The firm is engaged in non-invasive prenatal tests (NIPT), newborn screening tests, ophthalmologist specialist genome analysis tests, customized disease prediction tests, and direct to consumer (DTC) genetic tests, among others. In addition, the Company is developing genome-related software.
See Also
What is Eone Diagnomics Genome Center Co Ltd's Research & Development?
Research & Development
-1.5B
KRW
Based on the financial report for Sep 30, 2025, Eone Diagnomics Genome Center Co Ltd's Research & Development amounts to -1.5B KRW.
What is Eone Diagnomics Genome Center Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
13%
Over the last year, the Research & Development growth was -1%. The average annual Research & Development growth rates for Eone Diagnomics Genome Center Co Ltd have been 34% over the past three years , 13% over the past five years .
